Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

University of South Florida60 enrolled

Overview

This is an observational study collecting patient/caregiver reports on suspected medication/drug-induced acute porphyria attacks, as well as safe use of drugs previously labeled "unsafe" or with unknown risk. Participants will be recruited through the RDCRN Contact Registry for the Porphyrias Consortium. The study will be advertised on the Consortium website and through the American Porphyria Foundation's social media network.

Contact Registrants will be sent an email invitation describing the study. A unique link will be generated for each registrant and included in the email invitation. After 2 weeks, a second email invitation will be sent to the registrants who have not yet participated. After 1 month, a third email invitation will be sent to the registrants who have not yet participated. We may send additional emails periodically (e.g. every 6-12 months) to subjects enrolled to remind them to complete new surveys if they have taken any other medications of interest or have experienced any new reactions/attacks. If the registrant wants to participate in the study, he/she will follow the survey link in the email invitation, which directs him/her to an IRB-approved online consent form. If the participant consents to participate, he/she will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and "uneventful use of possibly risky medication". If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of "Medications of Interest" and report current or past use.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Porphyrias

Interventions

Web-based SurveyOTHER

Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and "uneventful use of possibly risky medication". If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of "Medications of Interest" and report current or past use.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Able to read and write in English * Enrolled in the RDCRN PC Contact Registry * Self-reported patient or caregiver of patient with acute porphyria There are no restrictions on age, sex or ethnicity. However, the following criteria will be applied to those reports that are considered evaluable (analyzed and scored): 1. Medication name must be specified 2. The data elements required in the scoring system must be complete Exclusion Criteria: * Unable to provide informed consent and complete forms

Locations (1)

University of South Florida Data Management Coordinating Center

Tampa, Florida, United States

Outcomes

Primary Outcomes

Acute Attack Form

Designed to capture PBG levels, characteristics of the acute attack, timing of medication administration, and pharmacological information on the medication.

Time frame: 5 years from study start

Uneventful Use of Possible Risky Medication Form

Designed to capture details of medication in question, ALA/PGB results during use of medication in questions, concomitant medication use, diet history, and alcohol use.

Time frame: 5 years from study start

Use of Medications of Interest Form

Designed to assess medications used by category and effects of each.

Time frame: 5 years from study start

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.